Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Researchers develop new approach to target cells affected by motor neurone disease

The technique could lead to safer and more effective gene therapies for the neurodegenerative disease

- PMLiVE

Top-10 ways for Pharma to leverage AI according to…AI

Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s remarkable to see the progress made in the technology compared to...

Impetus Digital

- PMLiVE

Eli Lilly announces new $4.5bn US site for manufacturing and drug development

The Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers

- PMLiVE

GSK receives CHMP recommendation for meningococcal disease vaccine Menveo

The new presentation would offer healthcare providers an option that does not require reconstitution before use

- PMLiVE

NHS England begins newborn screening programme to identify rare genetic conditions

The Generation Study is aiming to screen 100,000 newborns for more than 200 diseases

- PMLiVE

Beyond awareness: How employers can support those with chronic health conditions like PCOS

As part of PCOS Awareness Month, Dr Tayyibah Ali takes a look at the ways employers can help support colleagues with chronic conditions like PCOS

Mednet

- PMLiVE

Unlocking innovation: The power of diversity at Mednet

We explore how diversity and inclusion drive the innovation that's critical to business success.

Mednet

- PMLiVE

How patients are transforming cancer care: insights from ESMO on patient-centric oncology

By Inizio

- PMLiVE

Stats without stories: why journalists aren’t covering your data

By Christopher Silverwood

- PMLiVE

Results from Global Pharmaceutical Customer Experience survey

UCB and J&J Innovative Medicine come out on top, while customer experience is in a state of flux

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD

Approximately 300,000 patients in the US will be eligible for the therapy

- PMLiVE

Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront

One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links